title: [Anti-retroviral treatment in patients with AIDS and mycobacterial diseases].
abstract: Tuberculosis and other mycobacterial diseases are frequent coinfections in AIDS patients with an increased related mortality. In this review we have updated the treatment of the main mycobacterial diseases (tuberculosis and Mycobacterium avium disease), under the scope of pharmacological interactions between antimycobacterial drugs, specially rifampicin and clarithromycin, and anti-retroviral drugs. Antimycobacterial treatment schemes, their duration, primary and secondary chemoprophylaxis and the optimal time to start the anti-retroviral therapy are analized. Finally, the immnune reconstitution inflammatory syndrome and its treatment are discussed.
authors.affiliation: División B, HIV/sida, Hospital de Enfermedades Infecciosas F. J. Muñiz, Buenos Aires.
authors.forename: Marcelo E
authors.initials: ME
authors.lastname: Corti
authors.forename: Domingo J
authors.initials: DJ
authors.lastname: Palmero
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D009164:Mycobacterium Infections / Q000175:diagnosis / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D044966:Anti-Retroviral Agents; D017291:Clarithromycin; D012293:Rifampin